These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 12063982)
1. Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients. Torzilli G; Makuuchi M; Ferrero A; Takayama T; Hui AM; Abe H; Inoue K; Nakahara K Hepatogastroenterology; 2002; 49(45):740-5. PubMed ID: 12063982 [TBL] [Abstract][Full Text] [Related]
2. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164 [TBL] [Abstract][Full Text] [Related]
3. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve]. Kim MJ; Bae KW; Seo PJ; Jeong IK; Kim JH; Lee BH; Bang KT; Kim DW; Song IH Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292 [TBL] [Abstract][Full Text] [Related]
4. Differential tumor markers and hepatitis markers profile in liver tumors. Khalifa A; Mady EA; Abadeer N; Kamal A Anticancer Res; 1999; 19(4A):2495-500. PubMed ID: 10470181 [TBL] [Abstract][Full Text] [Related]
5. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841 [TBL] [Abstract][Full Text] [Related]
6. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Tao LY; Cai L; He XD; Liu W; Qu Q Am Surg; 2010 Nov; 76(11):1210-3. PubMed ID: 21140686 [TBL] [Abstract][Full Text] [Related]
7. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma. Cui R; Wang B; Ding H; Shen H; Li Y; Chen X Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656 [TBL] [Abstract][Full Text] [Related]
8. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961 [TBL] [Abstract][Full Text] [Related]
9. Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma. Röcken C; Licht J; Roessner A; Carl-McGrath S J Clin Pathol; 2005 Oct; 58(10):1069-75. PubMed ID: 16189153 [TBL] [Abstract][Full Text] [Related]
10. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Uenishi T; Yamazaki O; Tanaka H; Takemura S; Yamamoto T; Tanaka S; Nishiguchi S; Kubo S Ann Surg Oncol; 2008 Feb; 15(2):583-9. PubMed ID: 17955299 [TBL] [Abstract][Full Text] [Related]
11. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases. Lamerz R; Runge M; Stieber P; Meissner E Anticancer Res; 1999; 19(4A):2489-93. PubMed ID: 10470180 [TBL] [Abstract][Full Text] [Related]
12. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases. Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469 [TBL] [Abstract][Full Text] [Related]
13. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures. Lempinen M; Isoniemi H; Mäkisalo H; Nordin A; Halme L; Arola J; Höckerstedt K; Stenman UH J Hepatol; 2007 Nov; 47(5):677-83. PubMed ID: 17640760 [TBL] [Abstract][Full Text] [Related]
14. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. Ozkan H; Kaya M; Cengiz A Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813 [TBL] [Abstract][Full Text] [Related]
15. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Nakamura S; Nouso K; Sakaguchi K; Ito YM; Ohashi Y; Kobayashi Y; Toshikuni N; Tanaka H; Miyake Y; Matsumoto E; Shiratori Y Am J Gastroenterol; 2006 Sep; 101(9):2038-43. PubMed ID: 16848811 [TBL] [Abstract][Full Text] [Related]
16. [Tumor markers--personal experience. The use of tumor markers for cancer of digestive organs]. Ishii M Gan To Kagaku Ryoho; 1991 May; 18(6):1059-65. PubMed ID: 1709347 [TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma. Okuda H; Shiratori K; Yamamoto M; Takasaki K; Nakano M J Gastroenterol Hepatol; 2006 May; 21(5):869-73. PubMed ID: 16704538 [TBL] [Abstract][Full Text] [Related]
18. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population. Chantajitr S; Wilasrusmee C; Lertsitichai P; Phromsopha N J Hepatobiliary Pancreat Surg; 2006; 13(6):537-42. PubMed ID: 17139428 [TBL] [Abstract][Full Text] [Related]
19. Comparison of alpha-fetoprotein with some other tumour markers in Malaysians with hepatocellular carcinoma. Lopez JB; Balasegaram M; Timor J; Thambyrajah V Malays J Pathol; 1997 Jun; 19(1):53-8. PubMed ID: 10879242 [TBL] [Abstract][Full Text] [Related]
20. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma. Tanaka Y; Kashiwagi T; Tsutsumi H; Nagasawa M; Toyama T; Ozaki S; Naito M; Ishibashi K; Azuma M Hepatogastroenterology; 1999; 46(28):2464-8. PubMed ID: 10522021 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]